Drugs News and Research

RSS

New Cellular Signature Reveals Why Some Prostate Cancers Resist Standard Treatment

A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment.

9 Jul 2025

New Software Boosts Genome Editing Accuracy for Genetic Therapies

This innovative software, CRISPRware, optimizes guide RNA design for genome editing, supporting research on genetic disorders and uncharacterized peptides.

9 Jul 2025

New Insights into Cell Membrane Energy Waves

Johns Hopkins researchers identify energy-generating waves on cancer cell membranes, revealing potential targets for slowing tumor growth and spread.

9 Jul 2025

Evidence for Neural Stem Cell-Based Therapies in Multiple Sclerosis

Research indicates that neural stem cell transplants could promote myelin repair in progressive multiple sclerosis, paving the way for innovative treatments.

8 Jul 2025

New Stem Cell Reports Perspective: Biomanufacturing in Low Earth Orbit

A new perspective article just published in Stem Cell Reports, “Biomanufacturing in low Earth orbit: A paradigm shift,” features insights from the ISS National Laboratory’s very own Program Director for In-Space Biomanufacturing Davide Marotta, Deputy Chief Scientist Donna Roberts, and Chief Scientist Michael Roberts, as well as leading researchers in regenerative medicine.

3 Jul 2025

Understanding the Bacterial Propeller Architecture Offers Hope Against Antibiotic Resistance

Scientists have studied a new target for antibiotics in the greatest detail yet – in the fight against antibiotic resistance.

2 Jul 2025

Fidelio Capital Partners with Alphalyse to Accelerate the Global Roll-Out of LC-MS Host Cell Protein Analytics

Alphalyse, a fast-growing Danish specialist contract research organization (CRO) that has developed GMP‑validated liquid‑chromatography mass‑spectrometry (LC‑MS) assays for host‑cell‑protein (HCP) impurity testing in biologic drugs, today announces that Fidelio Capital has acquired a majority stake in the company.

From Alphalyse A/S 2 Jul 2025

Fusion Genes Emerge as Key Drivers in Cancer Development

Fusion genes, arising from abnormal chromosomal rearrangements, are gaining recognition as pivotal players in cancer development. These genetic alterations result in the creation of hybrid genes with altered functions, often driving tumor progression.

25 Jun 2025

Novel Strategy for Combating High-Fat Diet-Induced Metabolic Dysfunction

Research on receptor FFA2 reveals how different activators influence metabolic processes, paving the way for innovative treatments for diabetes and obesity.

20 Jun 2025

New Study Reveals Varied CAR T-Cell Therapy Benefits in Large B-Cell Lymphoma

A study identifies three patient subgroups in large B-cell lymphoma, revealing distinct responses to CD19 CAR T cell therapy and enhancing precision medicine.

20 Jun 2025

UQ Tech Bringing Regenerative Medicines Closer Than Ever

Tiny gel droplets enhanced with University of Queensland technology could open new pathways to repairing and replacing damaged organs.

20 Jun 2025

Researchers Develop Promising Vaccine for Vaginal Yeast Infections

The UGA vaccine offers a potential breakthrough in combating vaginal yeast infections, aiming to reduce reliance on antifungal drugs amid growing resistance.

18 Jun 2025

Bio-Rad Extends Anti-Idiotypic Antibody and SpyCatcher Reagent Ranges for Bioanalysis and Antibody Drug Development

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to pertuzumab (Perjeta), guselkumab (Tremfya), canakinumab (Ilaris), belimumab (Benlysta), and the bispecific drug emicizumab (Hemlibra).

18 Jun 2025